|
WASHINGTON UNIVERSITY CO-CLINICAL IMAGING RESEARCH RESOURCE
|
5U24CA209837-02
|
$630,034
|
|
SHOGHI, KOORESH
|
WASHINGTON UNIVERSITY
|
|
Washington University Cancer Genomics and Outcomes Research STRENGTH Program
|
5R25CA190190-04
|
$180,001
|
|
GOVINDAN, RAMASWAMY
|
WASHINGTON UNIVERSITY
|
|
Vitamin D and HA Signaling in TNBC
|
5R01CA194500-04
|
$353,419
|
|
WELSH, JOELLEN
|
STATE UNIVERSITY OF NEW YORK AT ALBANY
|
|
Virtual Transportation as a Strategy to Reduce Resistance to Cigarette and e-Cigarette Graphic Health Warnings in Adolescents and Young Adults
|
5R01CA214587-03
|
$363,195
|
|
BLANTON, HART
|
TEXAS A&M UNIVERSITY
|
|
Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms
|
5U01CA200466-03
|
$1,563,388
|
|
BRAND, RANDALL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Using Single Cell Analysis to identify therapeutic vulnerabilities in leptomeningeal melanoma metastases
|
5R21CA216756-02
|
$224,460
|
|
SMALLEY, KEIRAN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Unraveling the molecular control of a pro-metastatic regulatory network in melanoma
|
5R01CA184804-03
|
$387,731
|
|
TAVAZOIE, SOHAIL
|
ROCKEFELLER UNIVERSITY
|
|
University of Louisville Cancer Education Program
|
5R25CA134283-07
|
$318,600
|
|
HEIN, DAVID
|
UNIVERSITY OF LOUISVILLE
|
|
Understanding the consequences of oncogenic mutations on FGFR signaling
|
5F31CA216915-02
|
$44,524
|
|
RYAN, MOLLY
|
YALE UNIVERSITY
|
|
Tumor immune and glycan biomarkers for progressive prostate cancer
|
1R01CA212409-01A1
|
$563,176
|
|
WU, JENNIFER
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Triple-exon Reporter HTS Screen: Discovery of Novel Pre-mRNA Splicing Modulators
|
5R01CA214759-02
|
$418,321
|
|
WEBB, THOMAS
|
SRI INTERNATIONAL
|
|
Training in Interprofessional Education for Palliative Care in Oncology
|
5R25CA203637-02
|
$293,452
|
|
PFEIFER, MARK
|
UNIVERSITY OF LOUISVILLE
|
|
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
|
5R01CA205150-03
|
$605,252
|
|
HEYMACH, JOHN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The Structure, Function and Regulation of Eukaryotic DNA Replication Initiator Complexes
|
5R01CA030490-37
|
$610,461
|
|
BOTCHAN, MICHAEL
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
The Role of Trisomy 21 in Hematopoiesis and Leukemogenesis
|
5F31CA196231-04
|
$31,044
|
$31,044
|
LIGGETT, LUTHER
|
UNIVERSITY OF COLORADO DENVER
|
|
The role of the SCF/FBW7 ubiquitin ligase complex in hematopiesis and leukemia.
|
5R01CA133379-10
|
$381,375
|
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
The role of the p63-RBM38 loop in tumor suppression
|
5R01CA195828-03
|
$359,138
|
|
CHEN, XINBIN
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
The Role of Structural Factors in Mammography Screening Behavior in the United States
|
5F31CA210399-02
|
$36,028
|
|
DEMB, JOSHUA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
The Role of Protein Kinases in NRF2-driven Lung Squamous Cell Carcinoma
|
1R01CA216051-01A1
|
$500,167
|
|
WEISSMAN, BERNARD
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
The role of NRF2 in reflux-induced esophageal adenocarcinomas
|
1R01CA224366-01
|
$351,131
|
|
EL-RIFAI, WAEL
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2
|
5R01CA156744-08
|
$368,125
|
|
SUN, YI
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
The role of entosis in human cancers
|
5R01CA154649-08
|
$402,471
|
|
OVERHOLTZER, MICHAEL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
The Role of Cereblon Pathways in Myeloma
|
5R01CA183968-05
|
$446,267
|
|
STEWART, ALEXANDER
|
MAYO CLINIC ARIZONA
|
|
The role of CADM1 in malignant melanoma
|
5K99CA207855-02
|
$109,440
|
|
HARTSOUGH, EDWARD
|
THOMAS JEFFERSON UNIVERSITY
|
|
The role of butyrate-producing bacteria in CIMP colorectal cancer tumorigenesis
|
5R01CA205028-02
|
$373,092
|
|
WILLIAMS, BRENT
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role and mechanism of FTO in leukemogenesis and drug response
|
5R01CA214965-03
|
$444,571
|
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
The p62/MEKK3 complex in mTORC1 activation
|
5R01CA192642-04
|
$446,063
|
|
DIAZ MECO CONDE, MARIA
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
The molecular mechanisms of metabolism reprogramming in mutant Kras/Ink4a-driven pancreatic ductal adenocarcinoma
|
5R01CA207031-02
|
$366,000
|
|
CHIAO, PAUL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The Functional Role of LGR5 in Colon Cancer
|
5R01CA208063-02
|
$344,269
|
|
WANG, JING
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
The Functional Role of GRM3 in Colon Cancer
|
5R01CA215389-02
|
$344,269
|
|
WANG, JING
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
The Effect Of Cohesin Mutations In Hematologic Malignancies
|
5F31CA216976-02
|
$38,609
|
$38,609
|
MCNULTY, MAUREEN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Early Detection Research Network: Data Management and Coordinating Center
|
5U24CA086368-18
|
$3,911,862
|
|
FENG, ZIDING
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
The Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin Signaling
|
5R01CA217207-02
|
$489,796
|
|
SU, GLORIA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-06
|
$346,525
|
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The Annual Blood Brain Barrier Consortium Meeting
|
5R13CA086959-17
|
$5,000
|
|
NEUWELT, EDWARD
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-07
|
$413,844
|
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Tennessee Valley Cooperative Human Tissue Network
|
5UM1CA183727-06
|
$986,029
|
|
WASHINGTON, MARY
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Telomere-related Genomic Instability in Early Colorectal Carcinogenesis
|
5R21CA205434-02
|
$156,379
|
|
TANAKA, HIROMI
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Targeting vismodegib-resistant tumors using BH3 mimetics
|
5R01CA196851-03
|
$346,985
|
|
KIM, JAMES
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Targeting tissue factor as a novel oncotarget for immunotherapy of triple negative breast cancer
|
1R21CA216697-01A1
|
$203,580
|
|
HU, ZHIWEI
|
OHIO STATE UNIVERSITY
|
|
Targeting the Unfolded Protein Response in PanNETs
|
1R01CA219815-01A1
|
$487,325
|
|
OAKES, SCOTT
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Targeting the Notch:Myc axis in leukemia/lymphoma
|
1R01CA215518-01A1
|
$468,293
|
|
PEAR, WARREN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Targeting the GFI1-LSD1 Axis in T-Cell Acute Lymphoblastic Leukemia
|
5R01CA201235-02
|
$348,273
|
|
ENGEL, MICHAEL
|
UNIVERSITY OF UTAH
|
|
Targeting the epithelial to mesenchymal transition-mediated chemoresistance in breast cancer
|
5R01CA205418-03
|
$345,356
|
|
GAO, DINGCHENG
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Targeting SHP2 as a precision medicine for the treatment of HER2-positive breast cancer
|
1R01CA213996-01A1
|
$343,125
|
|
AGAZIE, YEHENEW
|
WEST VIRGINIA UNIVERSITY
|
|
Targeting Mesenchymal Stem Cells in Head and Neck Cancer
|
5K08CA184915-04
|
$159,700
|
|
WATTS, TAMMARA
|
UNIVERSITY OF TEXAS MED BR GALVESTON
|
|
Targeting Mdm2-MdmX E3 Ligase for Treatment of Drug-Resistant Lymphoma
|
5R01CA208352-02
|
$373,760
|
|
WANG, XINJIANG
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Targeting lung and breast cancer cell oxidative metabolism with D-penicillamine and disulfiram
|
5F30CA213817-02
|
$34,592
|
|
FALLS, KELLY
|
UNIVERSITY OF IOWA
|
|
Targeting Kinesin Family Member 15 for the Treatment of Cancer
|
5R01CA214545-02
|
$623,043
|
|
GODWIN, ANDREW
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
Targeting Chromatin Modifications in Leukemia with Trisomy 21
|
5K08CA181340-05
|
$128,526
|
$64,263
|
LANE, ANDREW
|
DANA-FARBER CANCER INST
|
Total relevant funding to Down Syndrome for this search: $1,626,103
|